The Next Breakthrough in CML May Be Life Without Treatment / ASC4FIRST trial, ASC4START Trial, ASCEMBL Trial, Asciminib, ...
Who Owns the Message? Key Takeaways from OncoDaily’s Exclusive Brunch at ESMO 2026 ...
Who Owns the Message? Key Takeaways from OncoDaily’s Exclusive Brunch at ESMO 2026 ...
What Changed in Melanoma Immunotherapy Over 20 Years? / cancer, ESMO, immune response, Melanoma, Nicholas Restifo, OncoDaily, ...
Omid Hamid Honors Jeffrey Weber’s Legacy in Cancer Immunotherapy / Adjuvant Therapy, ASCO, cancer, cancer vaccines, ESMO, ...
Gustave Roussy International – Egypt shared on LinkedIn: “Empowering African healthcare professionals through education, collaboration, and excellence in breast cancer care ...
City of Hope / cancer, City of Hope, clinical trials, esmo 2026, ESMO26, kidney cancer, kidney cancer research, ...
VIKTORIA-1 shows gedatolisib maintained strong PFS benefit over alpelisib in PIK3CA-mutant HR+/HER2− breast cancer, including ...
AI Can Guide Cancer Drug Discovery, but Clinical Validation Still Matters / AI, artificial intelligence, cancer, clinical ...
Izalontamab Brengitecan Improves PFS in HR+/HER2− Breast Cancer in China / Bihui Li, Bin Liu, Bing Zhao, Binghe Xu, cancer, ...
At the Community Oncology Global Congress (COGC 2026), organized by OncoDaily, Amol Akhade, Senior Consultant in Medical ...
FLAURA2 shows early EGFR ctDNA clearance is prognostic but does not predict benefit from adding chemotherapy to first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results